Results 91 to 100 of about 26,436 (212)

Sintilimab Plus Lenvatinib with or Without Radiotherapy for Advanced Hepatocellular Carcinoma with Pulmonary Metastasis [PDF]

Chang Liu,1,2,* Weixing Jiang,3,* Juxian Sun,1,* Jingwei Cui,4 Dandan He,1 Shuqun Cheng,1 Jie Shi1 1Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, People’s Republic ...
Cheng S, He D, Jiang W, Cui J, Liu C, Shi J, Sun J   +6 more
core  

ALBI‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

Alimentary Pharmacology &Therapeutics, EarlyView.
ALBI‐6, a novel score combining albumin–bilirubin grade and interleukin‐6, showed improved prognostic discrimination compared with established scores in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab, supporting its potential use for risk stratification in this setting.
Paula Bark, Lucas Wiesmann, Simon Johannes Gairing, Kateryna Shmanko, Lukas Müller, Maximilian Moos, Fabian Stöhr, Dirk Graafen, Tilman Emrich, Felix Hahn, Daniel Pinto dos Santos, Bernhard Scheiner, Victoria Berit Berger, Matthias Pinter, Valentina Zarka, Florian P. Reiter, Andreas Geier, Najib Ben Khaled, Alexander Philipp, Christoph Springfeld, Aurelie Tomczak, Michael T. Dill, Constantin Scholz, Jens Mittler, Hauke Lang, Beate Katharina Straub, Roman Kloeckner, Tobias Bäuerle, Christian Markus Lange, Arndt Weinmann, Peter Robert Galle, Friedrich Foerster   +31 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial

Liver Cancer
Introduction: The phase 3 LEAP-002 study (NCT03713593) of advanced hepatocellular carcinoma (HCC) suggested improved antitumor activity of lenvatinib plus pembrolizumab versus lenvatinib alone with manageable safety, although overall survival (
Masatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, Kazushi Numata, Hiroyuki Marusawa, Tetsuya Hosaka, Naoya Kato, Masayuki Kurosaki, Manabu Morimoto, Tatsuya Yamashita, Hironori Koga, Tsutomu Masaki, Naoyoshi Yatsuzuka, Masato Suzuki, Satoshi Nagao, Shuichi Kaneko, Hiromitsu Kumada   +16 more
doaj   +1 more source

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives

, 2016
Ricardo Costa,1 Benedito A Carneiro,1,2 Sunandana Chandra,1,2 Sachin G Pai,1 Young Kwang Chae,1,2 Jason B Kaplan,1,2 Hannah B Garrett,1 Mark Agulnik,1,2 Peter A Kopp,3 Francis J Giles1,2 1Northwestern Medicine Developmental Therapeutics Institute ...
Costa R, Carneiro BA, Kaplan JB, Garrett HB, Pai SG, Chae YK, Kopp PA, Agulnik M, Giles FJ, Chandra S   +9 more
core  

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison [PDF]

, 2016
Lenvatinib is an oral, multiple receptor tyrosine kinase inhibitor. Preclinical drug metabolism studies showed unique metabolic pathways for lenvatinib in monkeys and rats.
Nijenhuis, Cynthia M., Schellens, Jan H M, Dubbelman, Anne Charlotte, Pharmacoepidemiology and Clinical Pharmacology, Critchley, David, Beijnen, Jos H., Sub Clinical Pharmacology, Mizuo, Hitoshi, Kawaguchi, Shinki, Shumaker, Robert, Jansen, Robert S, Rosing, Hilde   +11 more
core   +2 more sources

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis [PDF]

Jiayun Jiang,1 Hui Zhang,1 Jiejuan Lai,1 Shiyu Zhang,1 Yanjiao Ou,1 Yu Fu,2,* Leida Zhang1,* 1Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, People’s Republic of ...
Jiang J, Lai J, Zhang H, Fu Y, Ou Y, Zhang L, Zhang S   +6 more
core  

Modulation of cytochrome P450 activity by the anticancer drug lenvatinib

, 2022
Lenvatinib, commercially marketed as Lenvima®, is an oral drug approved for the treatment of thyroid cancer, hepatocellular carcinoma and renal cell carcinoma that acts as a tyrosine kinase inhibitor.
Ivančík, Martin
core  

Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria [PDF]

, 2018
Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials.
Toyoda, Masanori, Naoko Chayahara, Toru Mukohara, Chayahara, Naoko, Nibu, Ken-ichi, Masanori Toyoda, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami, Nagatani, Yoshiaki, Ito, Yasuhiro, Otsuki, Naoki, Toshihiko Kasahara, Goto, Hideaki, Miyauchi, Akira, Yoshinori Imamura, Mukohara, Toru, Imamura, Yoshinori, Yoshiaki Nagatani, Mitsuyoshi Hirokawa, Yasuhiro Ito, Hirokawa, Mitsuyoshi, Kiyota, Naomi, Naomi Kiyota, Suto, Hirotaka, Hideaki Goto, Kasahara, Toshihiko, Akihiro Miya, Minami, Hironobu, Hirotaka Suto, Miya, Akihiro, Akira Miyauchi   +31 more
core   +1 more source